BVS

Bioventus is a musculoskeletal medical-device business that spent 2022-2024 posting deep GAAP losses (-$159M, -$156M, -$36M) but has clearly inflected: FY2025 delivered $22.7M net income (+162.9%), operating income of $54.0M (+455.2%) on a 9.5% operating margin, and diluted EPS of $0.33. The headline 31.8x P/E overstates how expensive this is because GAAP EPS was still recovering off near-break-even — on the metrics management steers to, Adjusted EBITDA reached $116.3M (up from $108.9M) and operating cash flow was $74.7M against just $2.6M of capex, i.e. roughly $72M of free cash flow, a ~10% FCF yield on the $698M market cap. Backing out net debt (~$279M long-term + $15M current − $51M cash), EV/EBITDA is only ~8x, undemanding for a 68.3% gross-margin device maker. The real weakness is the top line: revenue of $568M actually fell 0.9% YoY and has been essentially stuck at $512-573M for four years — this is a margin/cash-flow turnaround story, not a growth story.

The balance sheet is improving but still carries the scars of the loss years: retained deficit of -$335M and liabilities/equity of 2.47x. The July 2025 refinancing helps materially — a new $300M term loan plus revolver retired the old 2019 facility, extended maturity to July 2030, is expected to save ~$2M in annual interest, and $150M of the floating SOFR exposure is now swapped, de-risking the capital structure that previously overhung the equity. Long-term debt already fell 9.5% and the current debt portion dropped 45%, consistent with the strong cash generation being used to deleverage.